Physician profile
Hemant Solomon
NPI 1518174747
$18,207.04
in general payments reported to CMS, 2019-2025
41 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,773 · 2020: $1,050 · 2021: $1,949 · 2022: $1,209 · 2023: $3,528 · 2024: $3,277 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,782 · Travel and Lodging: $2,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,782.22 |
| Travel and Lodging | $2,443.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4,393.00 | 2019-2025 | Lifevest |
| Abbott Laboratories | $3,497.91 | 2019-2024 | Aveir, Tendril, Jot Dx |
| Boston Scientific Corporation | $2,812.87 | 2019-2025 | Watchman Flx, Varithena Administration Pack, Emblem Mri S-Icd |
| Medtronic, INC. | $2,694.72 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Linq II |
| Medtronic Vascular, INC. | $817.15 | 2019-2020 | |
| Biotronik INC. | $763.31 | 2019-2024 | Amvia Edge |
| Novartis Pharmaceuticals Corporation | $388.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $276.28 | 2021-2024 | Camzyos |
| Janssen Pharmaceuticals, INC | $212.48 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $195.28 | 2019-2025 | Farxiga |
| Celgene Corporation | $168.48 | 2022-2024 | Camzyos |
| Biosense Webster, INC. | $162.74 | 2023-2025 | Carto 3, Qdot Micro Catheter |
| Amgen INC. | $159.45 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $127.94 | 2024 | Nexletol, Nexlizet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.78 | 2019-2025 | Jardiance |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $120.40 | 2019-2024 | |
| Irhythm Technologies, INC. | $119.03 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Normatec Industries, Lp | $113.77 | 2019 | |
| Teleflex LLC | $113.34 | 2022 | |
| Braemar Manufacturing, LLC | $96.44 | 2019 | |
| Biocompatibles, INC. | $89.84 | 2019 | |
| Medela LLC | $89.27 | 2019 | |
| Kestra Medical Technology Services, INC. | $72.82 | 2023-2025 | Assure Wcd |
| Bard Peripheral Vascular, INC. | $61.25 | 2022 | |
| Davol INC. | $59.13 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $56.07 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $45.60 | 2019 | |
| Cook Medical LLC | $44.05 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $42.20 | 2025 | Onpattro, Amvuttra |
| Edwards Lifesciences Corporation | $36.97 | 2019-2023 | Mitris Resilia Mitral Valve |
| Pfizer INC. | $35.20 | 2019-2024 | |
| Novo Nordisk INC | $33.06 | 2023-2024 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $30.99 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $30.09 | 2024-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $26.54 | 2024 | Arcalyst |
| Philips North America LLC | $19.90 | 2024 | (Br3) Coronary Other |
| Elutia, INC. | $19.64 | 2023 | |
| Cashflow Solutions, LLC | $18.69 | 2025 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Merit Medical Systems INC | $17.18 | 2021 | |
| Cardiva Medical, INC. | $12.14 | 2019 | |
| Glaxosmithkline, LLC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.